Обзор доказательных данных по применению даптомицина при грамположительных инфекциях | КМАХ

Обзор доказательных данных по применению даптомицина при грамположительных инфекциях

Клиническая Микробиология и Антимикробная Химиотерапия. 2016; 18(4):270-281

​ Попов Д.А., Зубарева Н.А., Дехнич А.В.
даптомицин липопептиды антибиотикорезистентность инфекции кожи и мягких тканей бактериемия эндокардит S. aureus Enterococcus spp
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2016; 18(4):270-281

Аннотация

Даптомицин является единственным клинически применяемым представителем циклических липопептидов. Он обладает выраженной бактерицидной активностью, в том числе в отношении микробных клеток в составе биоплёнок. В спектр активности даптомицина входят практически все клинически значимые грам(+) бактерии, включая штаммы, устойчивые к другим классам антимикробных препаратов. На настоящий момент даптомицин зарегистрирован по двум показаниям: осложнённые инфекции кожи и мягких тканей и инфекции кровотока, вызванные S. aureus, включая бактериемию и эндокардит. Однако есть многочисленные исследования и наблюдения, показывающие потенциальную возможность использования даптомицина и при ряде других заболеваний, таких как инфекции костей и суставов, фебрильная нейтропения и др., вызванных полирезистентными грам(+) штаммами.

Попов Дмитрий Александрович

ФГБУ «НЦССХ им. А.Н. Бакулева» Минздрава России, Москва, Россия

Зубарева Н.А.

ФГБОУ ВО «ПГМУ им. Е.А. Вагнера» Минздрава России, Пермь, Россия

Дехнич Андрей Владимирович

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

  • 1. Дехнич А.В., Данилов А.И. Даптомицин: обзор фармакологических, клинических и микробиологических параметров. Клиническая Микробиология и Антимикробная Химиотерапия 2010; 12(4):295-313.
  • 2. Wang S.Z., Hu J.T., Zhang C., Zhou W., Chen X.F., Jiang L.Y., Tang Z.H. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open 201424;4(6): e004744.
  • 3. Chao L., Zhi M., Mengmeng Y., Hongjun K., Hui L., Liang P., Jie H., Jun L., Feihu Z. Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag 2016; 12:1455-66.
  • 4. Cogo A., Gonzalez-Ruiz A., Pathan R., Hamed K. Realworld treatment of complicated skin and soft tissue infections with daptomycin: results from a large european registry (EU-CORE). Infect Dis Ther 2015;4(3):273-82.
  • 5. Claeys K.C., Zasowski E. J., Casapao A.M., et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2016; 60(10):5841-8.
  • 6. Browne C., Muszbek N., Chapman R., Marsh K., Gould I.M., Seaton R.A., Allen M. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. Int J Antimicrob Agents 2016; 47(5):357-61.
  • 7. Zhao M., Liang L., Ji L., Chen D., Zhang Y., Zhu Y., Patel K. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. Int J Antimicrob Agents 2016; 48(3):231-
  • 8. eaton R. A., Gonzalez-Ruiz A., Cleveland K. O., Couch K. A., Pathan R., Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15:18.
  • 9. Habib G., Lancellotti P., Antunes M.J., et al. 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (ESC). Eur Heart J 2015; 36(44):3075-128.
  • 10. Gonzalez-Ruiz A., Seaton R.A., Hamed K. Daptomycin: an evidence-based review of its role in the treatment of Grampositive infections. Infect Drug Resist 2016; 9:47-58.
  • 11. Montange D., Berthier F., Leclerc G., et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother 2014; 58(7):3991-6.
  • 12. Peñalba A.P., Furustrand T.U., Bétrisey B., Vogt S., Trampuz A., Borens O. Activity of bone cement loaded with daptomycin alone or in combination with gentamicin or PEG600 against Staphylococcus epidermidis biofilms. Injury 2015; 46(2):249-53.
  • 13. Park K.H., Chong Y.P., Kim S.H., et al. Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillinresistant Staphylococcus aureus. J Infect 2013; 67(6):556- 64.
  • 14. Rangaraj G., Cleveland K.O., Gelfand M.S. Comparative analysis of daptomycin and vancomycin in the treatment of vertebral osteomyelitis. Infect Dis Clin Pract 2014; 22(4):219-22.
  • 15. Malizos K., Sarma J., Seaton R.A., et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35(1):111- 8.
  • 16. Goutelle S., Roux S., Gagnieu M.C., et al. Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections. Antimicrob Agents Chemother 2016; 60(5):3148-51.
  • 17. Ma T.K-W., Leung C.B., Chow K. Mi., Kwan B.C., Li P.K.T., Szeto C.C. Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. Clinical Kidney J 2016; 9(4):616-23.
  • 18. Li P.K., Szeto C.C., Piraino B., et al. Peritoneal dialysisrelated infections recommendations: 2010 update. Perit Dial Int 2010; 30:393-423.
  • 19. Huen S.C., Hall I., Topal J., Mahnensmith R.L., Brewster U.C., Abu-Alfa A.K. Successful use of intraperitoneal daptomycin in the treatment of vancomycinresistant enterococcus peritonitis. Am J Kidney Dis 2009; 54:538-41.
  • 20. Roveta S., Marchese A., Schito G.C. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int J Antimicrob Agents 2008; 31:321-28.
  • 21. García-López L., M. Luis J.F., Criado-Illana M.T., Gómez-Sayago L., Heras-Benito M. Intraperitoneal administration of daptomycin in recurrent peritonitis with suspected biofilm. Nefrologia 2012; 32(2):139-42.
  • 22. Denetclaw T.H., Suehiro I., Wang P.K., Tolliver G.L. Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulasenegative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy. Ann Pharmacother 2014; 48(10):1376-9.
  • 23. Len O., Montejo M., Cervera C., et al. Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation. Transpl Infect Dis 2014; 16(4):532-8.
  • 24. Lübbert C., Rodloff A.C., Hamed K. Real-world treatment of Enterococcal Infections with daptomycin: insights from a large European Registry (EU-CORE). Infect Dis Ther 2015; 4(3):259-71.
  • 25. Kullar R., Sakoulas G., Deresinski S., van Hal S.J. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 2016; 71(3):576-86.
  • 26. Desai H., Wong R., Pasha A.K. A novel way of treating multidrug-resistant enterococci. N Am J Med Sci 2016; 8(5):229-31.
  • 27. Berti A.D., Wergin J.E., Girdaukas G.G., Hetzel S.J., Sakoulas G., Rose W.E. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012; 56(10):5046-53.
  • 28. Mehta S., Singh C., Plata K.B., et al. Beta-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56(12):6192-200.
  • 29. Rose W.E., Schulz L.T., Andes D., Striker R., Berti A.D., Hutson P.R., Shukla S.K. Addition of ceftaroline to daptomycin after emergence of daptomycinnonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56(10):5296-302.
  • 30. Dhand A., Bayer A.S., Pogliano J., et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-63.
  • 31. Palma D.M., Giuliano S., Cracchiolo A.N., et al. Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases. Infection 2016; 44(1):77-84.
  • 32. Tong S.Y., Nelson J., Paterson D.L., et al. CAMERA2 — combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials 2016; 17:170.
  • 33. Holubar M., Meng L., Deresinski S. Bacteremia due to methicillin-resistant Staphylococcus aureus: new therapeutic approaches. Infect Dis Clin North Am 2016; 30(2):491-507.
  • 34. Phee L., Hornsey M., Wareham D.W. In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. Eur J Clin Microbiol Infect Dis 2013; 32(10):1291-4.
  • 35. Randall C.P., Mariner K.R., Chopra I., O’Neill A.J. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother 2012; 57(1):637-9.
  • 36. Namtu K.C., Crain J.C., Messina A.F., Dumois J.A., Berman D.M. Clinical experience with daptomycin in pediatrics. Pharmacotherapy 2016; doi: 10.1002/ phar.1872.
  • 37. Karageorgos S. A., Miligkos M., Dakoutrou M., Tsioutis C. Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: A Systematic Review. J Pediatric Infect Dis Soc. 2016; 5(4):446-457.
  • 38. Cervera C., Sanroma P., González-Ramallo V.,. Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial). Infect Dis 2016; 8:1- 8.
  • 39. Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemother 2009; 64(3):447- 53.
  • 40. Stefani S., Campanile F., Santagati M., Mezzatesta M.L., Cafiso V., Pacini G. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents 2015; 46(3):278-89.
  • 41. Silverman J.A., Oliver N., Andrew T., Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-802.
  • 42. Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing guidelines. Proceedings of 46th ICAAC2006, A-630.
  • 43. Moise P. A., North D., Steenbergen J. N., et al. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9:617-24.
  • 44. Mariani P.G., Sader H.S., Jones R.N. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58:481-3.
  • 45. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., Weinstein R.A. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-7.
  • 46. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-1082.
  • 47. Kosowska-Shick K., Julian K., Brumbach A., Curley E., Whitener C., Parent L., Bogdanovich T. Characteristics of S. aureus strain causing endocarditis which acquired VISA and daptomycin-resistant phenotypes after daptomycin therapy. 46th Intersci Conf on Antimicrob Agents Chemother 2006, E-727.
  • 48. Sheth A., Carpenter C.F., Robinson-Dunn B. Reduced vancomycin susceptibility and daptomycin nonsusceptibility associated with treatment failure in 2 cases of MRSA bacteremia. 46th Intersci Conf on Antimicrob Agents Chemother 2006, C2-1159.
  • 49. Bell J.M., Walter L.J., Turnidge J.D., Jones R.N. Vancomycin hetero-resistance has a small but significant effect on the daptomycin minimum inhibitory concentration of Staphylococcus aureus. 46th Intersci Conf on Antimicrob Agents Chemother 2006, D-814.
  • 50. Munoz-Price L.S., Lolans K., Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005; 41:565-6.
  • 51. MсGrath D.M., Barbu E.M., Pasqualini R., Arap W., Quinn J.P., Murray B.E., Arias C.A. Resistance to Daptomycin in Vancomycin-Resistant Enterococcus faecalisis Associated with Alterations of Cell Membrane Potential and Surface Charge. Proceedings of ICAAC2010. C1-078.
  • 52. Bowker K.E., Noel A. R., Macgowan A.P. The relationship between daptomycin free drug AUC/ MIC, antibacterial effect and emergence of resistance in S. aureus. Proceedings of ICAAC2009. A1-1271.
  • 53. Bhavnani S. M., Ambrose P. G., Hammel J. P., Rubino C.M., Drusano GL. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother 2015; 60(3):1600-7.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились